Listen on:
Episodes
Wednesday Mar 01, 2023
Wednesday Mar 01, 2023
STUDIES REFERENCED
ROLE OF SCALP BIOPSIES IN BLACK WOMEN WITH HAIR LOSS
Douglas A et al. Scalp Biopsy Influences Diagnostic Accuracy and Treatment in Black Women with Alopecia: A Retrospective Study. J Am Acad Dermatol. 2023 Jan 31;S0190-9622(23)00157-3.
ORAL MINOXIDIL IN CHEMOTHERAPY RELATED HAIR LOSS
Kang J et al. Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: A retrospective cohort study. J Am Acad Dermatol 2022 Dec 13;S0190-9622(22)03261-3.
FOLLICULOTROPIC MYCOSIS FUNGOIDES
Paolino G et al. Widespread and eruptive comedonal lesions with alopecia. JAAD Case Rep . 2022 Nov 1;31:23-26.
Kreutzer and Effendy. Cicatricial Alopecia Related to Folliculotropic Mycosis Fungoides. Dermatol Ther (Heidelb). 2020 Oct;10(5):1175-1180
Gallo G et al Clinical and trichoscopic features in 18 cases of Folliculotropic Mycosis Fungoides with scalp involvement. Scientific Reports. 2021 May 18;11(1):10555.
ATRICHIA WITH PAPULES LESIONS
Boisen J et al. Atrichia With Papular Lesions Confirmed via Genetic Testing: A Case Report. Cureus 2022 Dec; 14(12): e32562.
Zlotogorski A, Panteleyev AA, Aita VM, Christiano AM. Clinical and molecular diagnostic criteria of congenital atrichia with papular lesions. J Invest Dermatol 2002; 118: 887–890
Yip L, Horev L, Sinclair R, et al. Atrichia with papular lesions: a report of three novel human hairless gene mutations and a revision of diagnostic criteria. Acta Derm Venereol 2008; 88(4): 346–349.
Bergman R et al. The alopecias associated with vitamin D-dependent rickets type IIA and with hairless gene mutations: a comparative clinical, histologic, and immunohistochemical study. Arch Dermatol. 2005 Mar;141(3):343-51.
METHOTREXATE AND LIVER FIBROSIS
Atallah E et al. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. J Hepatol . 2023 Jan 23;S0168-8278(23)00020-X.
Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey JJ. Risk of liver injury among methotrexate users: a meta-analysis of randomised controlled trials. Semin Arthritis Rheum 2015;45(2):156–162
Cheema HI et al. Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis. J Investig Med. 2022 Oct;70(7):1452-1460.
Monday Feb 20, 2023
Monday Feb 20, 2023
STUDIES REFERENCED
PATHOLOGY OF NON SCARRING AND SCARRING ALOPECIA
Amanda Araujo Dos Reis Botega et al. Scarring versus Non-Scarring Alopecia: An Interobserver Histopathological Reproducibility Study Skin Appendage Disord. 2023 Jan;9(1):34-41. doi: 10.1159/000526966. Epub 2022 Nov 25.
HYDROXYCHLOROQUINE AND RETINOPATHY RISK
Ronald B Melles RB et al. Hydroxychloroquine Dose and Risk for Incident Retinopathy : A Cohort Study. Ann Intern Med. 2023 Jan 17.
LOW DOSE NALTREXONE IN LICHEN PLANOPILARIS
Lajevardi et al. The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled trial. J Dermatol Treat. Jun 2020
Hamel RK et al. Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study. Cureus Jan 2023.
Toledo-Pastrana et al. Perifollicular Erythema as a Trichoscopy Sign of Progression in Frontal Fibrosing Alopecia. Int J Trichology. 2013 Jul-Sep; 5(3): 151–153.
ACTINIC LICHEN PLANOPILARIS
Lalagianni N et al. Actinic lichen planopilaris: a new variant of lichen planopilaris triggered by ultraviolet radiation. Clin Exp Dermatol. 2023 Feb 2;48(2):158-160.
FOLLICULITIS DECALVANS MICROBIOME STUDIES
Moreno-Arrones OM et al. Folliculitis decalvans has a heterogeneous microbiological signature and impaired immunological response. Dermatology. 2023 Jan 30.
Moreno-Arrones et al. Folliculitis decalvans microbiologic signature is specific for disease clinical phenotype. J Am Acad Dermatol. 2021 Nov;85(5):1355-1357.
TNF INHIBITORS IN DISSECTING CELLULITIS
Alzahrani M et al. Treatment of dissecting cellulitis of the scalp with tumor necrosis factor inhibitors: a retrospective multicenter STUDY. Clin Exp Dermatol. 2023 Jan 26;llad036.
Friday Dec 23, 2022
Friday Dec 23, 2022
The season finale summarizes the top 20 studies of the 2022 calendar year. This episode addresses studies in hair shedding, scarring alopecia, seborrheic dermatitis and hair straighteners (studies 12 to 20). Studies 1 to 11 are found in Part 1 (season 3 episode 9)
STUDIES IN HAIR SHEDDING/TELOGEN EFFLUVIUM/ COVID19
STUDY 12: Muller-Ramos P et al. Post-COVID-19 hair loss: prevalence and associated factors among 5,891 patients. Int J Dermatol 2022 Jan 26.
STUDY 13: Anna Carolina Miola et al. Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization. J Am Acad Dermatol. 2022
STUDY 14: Mazeto IFS et al. Ultrastructural evidence for anagen hair follicle infection with SARS-CoV-2 in early-onset COVID-19 effluvium. J Eur Acad Dermatol Venereol. 2022 Jun 20.
STUDIES IN SCARRING ALOPECIA
STUDY 15: Dubin C et al. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol. 2022 Mar;86(3):551-562. doi: 10.1016/j.jaad.2021.05.016
STUDY 16: Jamerson et al. Gene expression profiling suggests severe, extensive central centrifugal cicatricial alopecia may be both clinically and biologically distinct from limited disease subtypes Exp Dermatol. 2022 Jan
STUDY 17: Joshi TP et al. Prevalence of lichen planopilaris in the United States: A cross-sectional study of the All of Us research program. JAAD Int. 2022 Jun 13;8:69-70.
STUDY 18: Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.
STUDIES IN VARIOUS TOPICS
STUDY 19: Chang CJ et al. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Oct 17;djac165.
STUDY 20: Ying-Yi Lu et al. Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. J Dermatol. 2022 Sep 12.
STUDIES IN PART 1 of PODCAST
STUDIES IN AGA
STUDY 1: Qui Y et al. Systematic Review and Meta-analysis of the Association Between Metabolic Syndrome and Androgenetic Alopecia. Acta Derm Venereol. 2022 Feb 8;102:adv00645
STUDY 2: Cao L et al. Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022 Feb 28;1-7. doi: 10.25259/IJDVL_714_2021.
STUDY 3: Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;
STUDY 4: Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237.
STUDY 5: Gupta AK et al. Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022 Feb 2:e215743.
STUDY 6: Gupta AK and Bamimore M. Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.
STUDY 7: Gupta AK et al. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36
STUDY 8: Klein E et al. Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia; a retrospective chart review. J Cosmet Dermatol. 2022 Jun 1.
STUDY 9: Liang X et al. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022 Jul 11;9:905140.
STUDIES IN ALOPECIA AREATA
STUDY 10: King B et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 Mar 26.
STUDY 11: Anna Waśkiel-Burnat et al. Patients with alopecia areata are at risk of endothelial dysfunction: results of a case-control study. Clin Exp Dermatol. 2022 Mar 31.
Friday Dec 23, 2022
Friday Dec 23, 2022
The season finale summarizes the top 20 studies of the 2022 calendar year. This episode addresses studies in androgenetic alopecia and alopecia areata (studies 1 to 11). Studies 12 to 20 are found in Part 2 (season 3 episode 10)
STUDIES IN FEMALE PATTERN HAIR LOSS AND MALE PATTERN HAIR LOSS
STUDY 1: Qui Y et al. Systematic Review and Meta-analysis of the Association Between Metabolic Syndrome and Androgenetic Alopecia. Acta Derm Venereol. 2022 Feb 8;102:adv00645
STUDY 2: Cao L et al. Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022 Feb 28;1-7. doi: 10.25259/IJDVL_714_2021.
STUDY 3: Sanabria et al. Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;
STUDY 4: Jimenez-Cauhe J et al. Before-after study with 24-hour ambulatory blood pressure monitoring after the first dose of 5 mg oral minoxidil. J Am Acad Dermatol. 2022 Dec;87(6):e235-e237.
STUDY 5: Gupta AK et al. Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022 Feb 2:e215743.
STUDY 6: Gupta AK and Bamimore M. Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.
STUDY 7: Gupta AK et al. There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36
STUDY 8: Klein E et al. Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia; a retrospective chart review. J Cosmet Dermatol. 2022 Jun 1.
STUDY 9: Liang X et al. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022 Jul 11;9:905140.
STUDIES IN ALOPECIA AREATA
STUDY 10: King B et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 Mar 26.
STUDY 11: Anna Waśkiel-Burnat et al. Patients with alopecia areata are at risk of endothelial dysfunction: results of a case-control study. Clin Exp Dermatol. 2022 Mar 31.
STUDIES IN HAIR SHEDDING/TELOGEN EFFLUVIUM/ COVID19
STUDY 12: Muller-Ramos P et al. Post-COVID-19 hair loss: prevalence and associated factors among 5,891 patients. Int J Dermatol 2022 Jan 26.
STUDY 13: Anna Carolina Miola et al. Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization. J Am Acad Dermatol. 2022
STUDY 14: Mazeto IFS et al. Ultrastructural evidence for anagen hair follicle infection with SARS-CoV-2 in early-onset COVID-19 effluvium. J Eur Acad Dermatol Venereol. 2022 Jun 20.
STUDIES IN SCARRING ALOPECIA
STUDY 15: Dubin C et al. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol. 2022 Mar;86(3):551-562. doi: 10.1016/j.jaad.2021.05.016
STUDY 16: Jamerson et al. Gene expression profiling suggests severe, extensive central centrifugal cicatricial alopecia may be both clinically and biologically distinct from limited disease subtypes Exp Dermatol. 2022 Jan
STUDY 17: Joshi TP et al. Prevalence of lichen planopilaris in the United States: A cross-sectional study of the All of Us research program. JAAD Int. 2022 Jun 13;8:69-70.
STUDY 18: Joshi et al. Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.
STUDIES IN VARIOUS TOPICS
STUDY 19: Chang CJ et al. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Oct 17;djac165.
STUDY 20: Ying-Yi Lu et al. Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. J Dermatol. 2022 Sep 12.
Wednesday Dec 07, 2022
Wednesday Dec 07, 2022
STUDIES REFERENCED
ROLE OF CORTICOSTEROIDS IN THE JAK INHIBITOR ERA
Licata G et al (starts at 7:21). Management of alopecia areata in JAK-inhibitors era: are systemic and topical corticosteroids still useful? Int J Dermatol. 2022 Nov 13.
ALOPECIA AREATA AND PERIODONTITIS
Kim JS et al (starts at 17:15). Periodontitis and risk of alopecia areata: A nationwide population-based cohort study in Korea. J Eur Acad Dermatol Venereol. 2022 Nov 17.
ALOPECIA AREATA AND MICRONEEDLING
Arora A et al (starts at 23:33). Comparative Efficacy of Injection Triamcinolone Acetonide given Intralesionally and through Microneedling in Alopecia areata. Int J Trichology. 2022 Sep-Oct;14(5):156-161.
Chandrashekar BS et al (starts at 27:42). Alopecia areata-successful outcome with microneedling and triamcinolone acetonide. J Cutan Aesthet Surg. 2014 Jan;7(1):63-4.
HAIR LOSS IN TRANSGENDER INDIVIDUALS
C Cocchetti et al (starts at 32:04). Effects of hormonal treatment on dermatological outcome in transgender people: a multicentric prospective study (ENIGI). J Endocrinol Invest. 2022 Nov 8.
MICRONEEDLING TO TREAT ANDROGENETIC ALOPECIA
Lingling Jia et al (starts at 38:21). Effects of microneedling with 5% minoxidil topical solution combination therapy in treatment of androgenetic alopecia. J Cosmet Dermatol. 2022 Jul 21.
Dhurat R et al (starts at 40:18). A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology. 2013 Jan;5(1):6-11.
Liang X et al (starts at 43:49). Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: A Prospective, Single-Center, Parallel-Group, Evaluator Blinded, Randomized Trial. Front Med (Lausanne). 2022 Jul 11;9:905140.
Tuesday Nov 29, 2022
Tuesday Nov 29, 2022
A mix of recently published studies in hair loss
IRON PILL GASTRITIS
Koch R et al (starts at5 5:19). Case report: Rapid onset, ischemic-type gastritis after initiating oral iron supplementation. Front Med (Lausanne) 2022 Nov 3;9:1010897.
Laine LA et al. (starts at 9:17). Effect of oral iron therapy on the upper gastrointestinal tract. A prospective evaluation. Dig Dis Sci. (1988) 33:172–7. doi: 10.1007/BF01535729
COMPARISON OF HORIZONTAL VS VERTICAL SECTIONING FOR SCALP BIOPSIES
Yadav et al (starts at 14:05). Vertical versus transverse sectioning in histopathological diagnosis of alopecia: A comparative study. Indian J Dermatol Venereol Leprol. 2022 Sep 17;1-4.
Du et al (starts at 22:40). Diagnostic value of horizontal versus vertical sections for scarring and non-scarring alopecia: a systematic review and meta-analysis. Eur J Dermatol . 2016 Aug 1;26(4):361-9. doi: 10.1684/ejd.2016.2797.
Nguyen J et al (starts at 27:13). The HoVert technique: A novel method for the sectioning of alopecia biopsies. J Cutan Pathol. 2011;38:401–6.
PERSISTENT HIVES AFTER LASER HAIR REMOVAL
Dorgham N et al (starts at 27:36). Severe persistent urticaria following laser hair reduction. J Cosmet Dermatol. 2022 Sep 15.
Landa N et al (starts at . Urticaria induced by laser epilation: a clinical and histopathological study with extended follow-up in 36 patients. Lasers Surg Med. 2012;44(5):384-389.
HAIR REPIGMENTATION FROM NILOTINIB
Kockerols CCB, Westerweel PE (starts at 34:24). Hair Repigmentation Induced by Nilotinib. N Engl J Med. 2022 Aug 11;387(6):e12. doi: 10.1056/NEJMicm2119953. Epub 2022 Aug 6.
SEBORRHEIC DERMATITIS AND OSTEOPOROSIS
Ying-Yi Lu et al (starts at 37:01) . Impact of seborrheic dermatitis on osteoporosis risk: A population-based cohort study. J Dermatol. 2022 Sep 12.
SEBORRHEIC DERMATITIS AND PARKINSON’S DISEASE
Tomic S et al (starts at 47:09). Seborrheic Dermatitis Is Related to Motor Symptoms in Parkinson's Disease. J Clin Neurol. 2022 Nov;18(6):628-634.
FINASTERIDE AND BLADDER CANCER.
Garg H et al (starts at 53:52). Impact of Finasteride on Survival in Bladder Cancer: A Retrospective Multi-institutional Database Analysis. Clin Genitourin Cancer. 2022 Oct 29;S1558-7673(22)00221-X
Monday Nov 21, 2022
Monday Nov 21, 2022
LEARNING OBJECTIVES
By the end of the podcast, the listener should be able to
Discuss the benefits of HCQ in LPP
Outline allergens that may be relevant in LPP/FFA
Discuss the benefits of LDOM in LPP
Describe the Renbok phenomenon and how it relates to FFA
Outline the potential triggers for EPDS
Describe the relationship between AKN and gout
EFFICACY OF HYDROXYCHLOROQUINE IN LICHEN PLANOPILARIS
Vastarella M et al (starts at 6:08). Efficacy and safety of hydroxychloroquine for the management of lichen planopilaris in a real-life setting. Ital J Dermatol Venerol. 2022 Jun;157(3):296-297.
Chiang C et al (starts at 14:17). Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. J Am Acad Dermatol. 2010 Mar;62(3):387-92.
Dhonncha EN et al (starts at 16:05). The role of hydroxychloroquine in the treatment of lichen planopilaris: A retrospective case series and review. Dermatol Ther. 2017 May;30(3).
ALLERGIC CONTACT DERMATITIS IN LICHEN PLANOPILARIS AND FRONTAL FIBROSING ALOPECIA
Prasad et al (starts at 18:38). Patch testing and contact allergen avoidance in patients with lichen planopilaris and/or frontal fibrosing alopecia: A cohort study J Am Acad Dermatol Aug 2020
Shtaynberger B et al (starts at 22:51). The Prevalence of Type IV Hypersensitivity in Patients With Lichen Planopilaris and Frontal Fibrosing Alopecia. Dermatitis. 2022 Oct 17.
USE OF ORAL MINOXIDIL IN LICHEN PLANOPILARIS
Vano-Galvan S et al (starts at 36:42). Oral minoxidil improves background hair thickness in lichen planopilaris. J Am Acad Dermatol 2021 Jun;84(6):1684-1686.
Giuseppe Gallo et al (starts at 37:45). Low-dose oral minoxidil in female patients with lichen planopilaris: Real-life experience. J Eur Acad Dermatol Venereol. 2022 Aug 16
RENBOK PHENOMENON IN FRONTAL FIBROSING ALOPECIA
Sławińska M et al (starts at 42:29). Frontal fibrosing alopecia sparing a dermal melanocytic nevus: a report of two cases of Renbök phenomenon. J Eur Acad Dermatol Venereol. 2022 Dec;36(12):e1042-e1043.
EROSIVE PUSTULAR DERMATOSIS AND SHINGLES
Salah NB et al (starts at 45:21). Erosive pustular dermatosis of the scalp in the COVID-19 era. J Cosmet Dermatol. 2022 Nov 14.
Akpandak I et al (starts at 50:55). Assessment of Herpes Zoster Risk Among Recipients of COVID-19 Vaccine. JAMA Netw Open 2022 Nov 1;5(11):e2242240.
RISK OF GOUT IN ACNE KELOIDALIS
Eran Shavit et al (starts at 53:40). The burden of gout in acne keloidalis nuchae-Insights from a population-based study. J Cosmet Dermatol. 2022 Nov 8.
Tuesday Nov 15, 2022
Tuesday Nov 08, 2022
Tuesday Nov 08, 2022
Studies in Androgenetic Alopecia and Alopecia Areata
STUDIES REFERENCED
MINOXIDIL CONCENTRATIONS
Singh et al (starts at 10:10). Does topical minoxidil at concentrations higher than 5% provide additional clinical benefit? Clin Exp Dermatol. 2022 Nov;47(11):1951-1955
Olsen EA, Dunlap FE, Funicella T et al (starts at 13:22). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47: 377–85
McCoy J, Goren A, Kovacevic M, Shapiro J (starts at 16:02). Minoxidil dose response study in female pattern hair loss patients determined to be non-responders to 5% topical minoxidil. J Biol Regul Homeost Agents 2016;30: 1153–5
Goldust M (starts at 17:25). Minoxidil 15% solution versus minoxidil 5%solution in the treatment of androgenetic alopecia. Br JDermatol 2020;183(Suppl): 91 (abstract BH107)
Ghonemy S, Alarawi A, Bessar H (starts at 18:11). Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgeneticalopecia: a trichoscopic evaluation. J Dermatolog Treat 2021;32: 236–41
JAK INHBITORS FOR ANDROGENETIC ALOPECIA
Casale F et al (starts at 22:19). Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia? Int J Dermatol. 2022 Nov;61(11):e457-e458.
BOTOX FOR ANDROGENETIC ALOPECIA
English RS Jr and Ruiz S (starts at 29:30). Use of Botulinum Toxin for Androgenic Alopecia: A Systematic Review. Skin Appendage Disord. 2022 Mar;8(2):93-100
Shon U, Kim MH, Lee DY, Kim SH, Park BC (starts at 33:48). The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism. J Am Acad Dermatol. 2020 Dec;83(6):1838–9.
PLATELET RICH PLASMA TREATMENTS FOR ANDROGENETIC ALOPECIA
Gupta AK and Bamimore M (starts at 39:09). Platelet-Rich Plasma Monotherapies for Androgenetic Alopecia: A Network Meta-Analysis and Meta-Regression Study. J Drugs Dermatol. 2022 Sep 1;21(9):943-952.
de Oliveira AFQ et al (starts at 42:25). Use of autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and meta-analysis. J Dermatolog Treat. 2022 Oct 31:1-11.
LOW DOSE ORAL MINOXIDIL SIDE EFFECTS
Dlova et al (starts 45:41). Pericardial, pleural effusion and anasarca: A rare complication of low-dose oral minoxidil for hair loss. JAAD Case Rep. 2022 Aug 11;28:94-96.
Randolph M, Tosti A (starts at 53:22). Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021;84(3): 737-746.
LOW DOSE ORAL MINOXIDIL EFFICACY AND SAFETY
Gupta AK et al (starts at 57:33). There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for Androgenetic Alopecia: Findings from a Systematic Review with Meta-Regression Analyses. Skin Appendage Disord. 2022 Sep; 8(5): 355–36
JAK INHIBITORS AND VENOUS THROMBOEMBOLISM
Chen T-L et al (starts at 1:02:14). Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis. JAMA Dermatol. 2022 Aug 24;e223516.
King B et al (1:05:33). Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022 Mar 26.
Misra D et al (starts at 1:11:19). Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box. Clin Rheumatol. 2022 Oct 20.
RISING PREVALENCE OF ALOPECIA AREATA IN JAPAN
Campos-Alberto E et al (starts at 1:13:00). Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: A descriptive study using Japan medical data center claims database. J Dermatol. 2022 Nov 2.
COVID VACCINATION AND ALOPECIA AREATA RISK
Tassone F et al (starts at 1:15:21). Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study. Vaccines (Basel). 2022 Sep 5;10(9):1467.
Nguyen B and Tosti A (starts at 1:21:22). Alopecia areata after COVID-19. J Eur Acad Dermatol Venereol. 2022 Aug 11;10.1111/jdv.18491.
Babadjouni A et al (starts at 1:30:21). COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy. JAAD Case Rep . 2022 Nov;29:181-185.
Chen C-H et al (starts at 1:36:55). Intractable alopecia areata following the second dose of COVID-19 vaccination: Report of two cases. Dermatol Ther. 2022 Sep;35(9):e15689.
Monday Oct 24, 2022
Monday Oct 24, 2022
Recording of the Evidence Based Hair Podcast for the Oct 24, 2022 issue.
STUDIES REFERENCED
Han JJ et al (starts at 5:28) Association of resilience and perceived stress in patients with alopecia areata: A cross-sectional study. J Am Acad Dermatol. 2022 Jul;87(1):151-153.
Gressler J et al (starts at 20:55 ). Re-pigmentation of scalp hair - A feature of early melanoma. Am J Med. 2022 Sep 25;S0002-9343(22)00711-2.
Lackey A et al (starts at 24:09) Repigmentation of gray hairs with lentigo maligna and response to topical imiquimod. JAAD Case Rep. 2019 Dec; 5(12): 1015–1017
Nguyen et al (starts at 27:18). Characterizing and assessing the reliability of TikTok's most viewed alopecia-related videos. J Eur Acad Dermatol Venereol. 2022 Aug 14.
Nagrani NS, Goldberg LJ (starts at 37:24). Sebaceous gland atrophy in seborrheic dermatitis of the scalp; a pilot study. J Cutan Pathol. 2022 Nov;49(11):988-992.
Headington JT, Gupta AK, Goldfarb MT, et al (starts at 41:26). A morphometric and histologic study of the scalp in psoriasis. Paradoxical sebaceous gland atrophy and decreased hair shaft diameters without alopecia. Arch Dermatol. 1989;125:639-642.
Klein EJ et al (starts at 46:38). Supplementation and hair growth: A retrospective chart review of patients with alopecia and laboratory abnormalities. JAAD Int. 2022 Aug 30;9:69-71.
Chang CJ et al (starts at 59:21). Use of Straighteners and Other Hair Products and Incident Uterine Cancer. J Natl Cancer Inst. 2022 Oct 17;djac165.